ARGUN AKCAKANAT to Aged
This is a "connection" page, showing publications ARGUN AKCAKANAT has written about Aged.
Connection Strength
0.070
-
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer. 2008 Jun; 112(11):2352-8.
Score: 0.013
-
Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer. 2006 Jan 01; 118(1):123-8.
Score: 0.011
-
NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004 Jul; 54(1):95-100.
Score: 0.010
-
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
Score: 0.007
-
Pulmonary function after laparoscopic cholecystectomy in the elderly. Br J Surg. 1997 Apr; 84(4):579.
Score: 0.006
-
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
Score: 0.005
-
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
Score: 0.005
-
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
Score: 0.005
-
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84.
Score: 0.005
-
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res. 2012 Oct 26; 14(5):R138.
Score: 0.004